CYP2D6
| Symbol | – |
|---|---|
| HGNC ID | – |
| Alternative symbols | – |
| Entrez Gene | – |
| OMIM | – |
| RefSeq | – |
| UniProt | – |
| Chromosome | – |
| Locus supplementary data | – |
Cytochrome P450 2D6 (CYP2D6) is an enzyme that in humans is encoded by the CYP2D6 gene. CYP2D6 is primarily expressed in the liver. It is also highly expressed in areas of the central nervous system, including the substantia nigra.
CYP2D6, a member of the cytochrome P450 mixed-function oxidase system, is one of the most important enzymes involved in the metabolism of xenobiotics in the body. In particular, CYP2D6 is responsible for the metabolism and elimination of approximately 25% of clinically used drugs, via the addition or removal of certain functional groups – specifically, hydroxylation, demethylation, and dealkylation.<ref name="pmid19645588">,
New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme, Drug Metabolism Reviews, 2009, Vol. 41(Issue: 4), pp. 573–643, DOI: 10.1080/03602530903118729, PMID: 19645588,</ref> CYP2D6 also activates some prodrugs. This enzyme also metabolizes several endogenous substances, such as hydroxytryptamines, neurosteroids, and both m-tyramine and p-tyramine which CYP2D6 metabolizes into dopamine in the brain and liver.<ref name="pmid19645588"/><ref name="Brain CYP2D6">, The endogenous substrates of brain CYP2D, European Journal of Pharmacology, Vol. 724, pp. 211–8, DOI: 10.1016/j.ejphar.2013.12.025, PMID: 24374199,</ref>
Considerable variation exists in the efficiency and amount of CYP2D6 enzyme produced between individuals. Hence, for drugs that are metabolized by CYP2D6 (that is, are CYP2D6 substrates), certain individuals will eliminate these drugs quickly (ultrarapid metabolizers) while others slowly (poor metabolizers). If a drug is metabolized too quickly, it may decrease the drug's efficacy while if the drug is metabolized too slowly, toxicity may result.<ref name="pmid22185816"/> So, the dose of the drug may have to be adjusted to take into account of the speed at which it is metabolized by CYP2D6.<ref name="pmid22515611">,
Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment, Pharmacogenomics, Vol. 13(Issue: 6), pp. 691–7, DOI: 10.2217/pgs.12.27, PMID: 22515611,</ref>
Other drugs may function as inhibitors of CYP2D6 activity or inducers of CYP2D6 enzyme expression that will lead to decreased or increased CYP2D6 activity respectively. If such a drug is taken at the same time as a second drug that is a CYP2D6 substrate, the first drug may affect the elimination rate of the second through what is known as a drug-drug interaction.<ref name="pmid22185816">,
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance, Drug Metabolism and Pharmacokinetics, 2012, Vol. 27(Issue: 1), pp. 55–67, DOI: 10.2133/dmpk.DMPK-11-RV-121, PMID: 22185816,</ref>
Gene
The gene is located near two cytochrome P450 pseudogenes on chromosome 22q13.1. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.<ref>
Entrez Gene: CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6(link). {{{website}}}.
</ref>
Genotype/phenotype variability
CYP2D6 shows the largest phenotypical variability among the CYPs, largely due to genetic polymorphism. The genotype accounts for normal, reduced, and non-existent CYP2D6 function in subjects. Pharmacogenomic tests are now available to identify patients with variations in the CYP2D6 allele and have been shown to have widespread use in clinical practice.<ref name="PMID24413808" /> The CYP2D6 function in any particular subject may be described as one of the following:<ref name="pmid11851634">,
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs, British Journal of Clinical Pharmacology, Vol. 53(Issue: 2), pp. 111–22, DOI: 10.1046/j.0306-5251.2001.01548.x, PMID: 11851634, PMC: 1874287,</ref>
- poor metabolizer – little or no CYP2D6 function
- intermediate metabolizers – metabolize drugs at a rate somewhere between the poor and extensive metabolizers
- extensive metabolizer – normal CYP2D6 function
- ultrarapid metabolizer – multiple copies of the CYP2D6 gene are expressed, so greater-than-normal CYP2D6 function occurs
A patient's CYP2D6 phenotype is often clinically determined via the administration of debrisoquine (a selective CYP2D6 substrate) and subsequent plasma concentration assay of the debrisoquine metabolite (4-hydroxydebrisoquine).<ref name="pmid19102711">,
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity, Pharmacogenomics, Vol. 10(Issue: 1), pp. 17–28, DOI: 10.2217/14622416.10.1.17, PMID: 19102711,</ref>
The type of CYP2D6 function of an individual may influence the person's response to different doses of drugs that CYP2D6 metabolizes. The nature of the effect on the drug response depends not only on the type of CYP2D6 function, but also on the extent to which processing of the drug by CYP2D6 results in a chemical that has an effect that is similar, stronger, or weaker than the original drug, or no effect at all. For example, if CYP2D6 converts a drug that has a strong effect into a substance that has a weaker effect, then poor metabolizers (weak CYP2D6 function) will have an exaggerated response to the drug and stronger side-effects; conversely, if CYP2D6 converts a different drug into a substance that has a greater effect than its parent chemical, then ultrarapid metabolizers (strong CYP2D6 function) will have an exaggerated response to the drug and stronger side-effects.<ref name="pmid17708140">,
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects, American Family Physician, Vol. 76(Issue: 3), pp. 391–6, PMID: 17708140,</ref>
Genetic basis of variability
The genetic basis for CYP2D6-mediated metabolic variability is the CYP2D6 allele, located on chromosome 22. Subjects possessing certain allelic variants will show normal, decreased, or no CYP2D6 function, depending on the allele. Pharmacogenomic tests are now available to identify patients with variations in the CYP2D6 allele and have been shown to have widespread use in clinical practice.<ref name="PMID24413808">,
The role of pharmacogenomic testing in psychiatry: Real world examples, The Australian and New Zealand Journal of Psychiatry, Vol. 48(Issue: 8), pp. 778, DOI: 10.1177/0004867413520050, PMID: 24413808,</ref>
| CYP2D6 enzyme activity for selected alles<ref name="Droll_1998"/><ref>
CYP2D6 allele nomenclature(link). {{{website}}}.
| |
| Allele | CYP2D6 activity |
| CYP2D6*1 | normal |
| CYP2D6*2 | normal |
| CYP2D6*3 | none |
| CYP2D6*4 | none |
| CYP2D6*5 | none |
| CYP2D6*6 | none |
| CYP2D6*7 | none |
| CYP2D6*8 | none |
| CYP2D6*9 | decreased |
| CYP2D6*10 | decreased |
| CYP2D6*11 | none |
| CYP2D6*12 | none |
| CYP2D6*13 | none |
| CYP2D6*14 | none |
| CYP2D6*15 | none |
| CYP2D6*17 | decreased |
| CYP2D6*19 | none |
| CYP2D6*20 | none |
| CYP2D6*21 | none |
| CYP2D6*29 | decreased |
| CYP2D6*31 | none |
| CYP2D6*38 | none |
| CYP2D6*40 | none |
| CYP2D6*41 | decreased |
| CYP2D6*42 | none |
| CYP2D6*68 | none |
| CYP2D6*92 | none |
| CYP2D6*100 | none |
| CYP2D6*101 | none |
| CYP2D6 duplication | increased |
Ethnic factors in variability
Race is a factor in the occurrence of CYP2D6 variability. The lack of the liver cytochrome CYP2D6 enzyme occurs approximately in 7–10% in white populations, and is lower in most other ethnic groups such as Asians and African-Americans at 2% each.<ref>Linda Lane, Scott, Julie, Beth,
Pharmacology and the Nursing Process, Toronto:Mosby Elsevier, 2007, ISBN 9780779699711, Pages: 25,</ref> The occurrence of CYP2D6 ultrarapid metabolizers appears to be greater among Middle Eastern and North African populations.<ref name="pmid9241658">, Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians, Pharmacogenetics, Vol. 7(Issue: 3), pp. 187–91, DOI: 10.1097/00008571-199706000-00003, PMID: 9241658,</ref>
Caucasians with European descent predominantly (around 71%) have the functional group of CYP2D6 alleles, while functional alleles represent only around 50% of the allele frequency in populations of Asian descent.<ref name="pmid11972444">,
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants, Pharmacogenomics, Vol. 3(Issue: 2), pp. 229–43, DOI: 10.1517/14622416.3.2.229, PMID: 11972444,</ref>
This variability is accounted for by the differences in the prevalence of various CYP2D6 alleles among the populations–approximately 10% of whites are intermediate metabolizers, due to decreased CYP2D6 function, because they appear to have the non-functional CYP2D6*4 allele,<ref name="Droll_1998">,
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians, Pharmacogenetics, Vol. 8(Issue: 4), pp. 325–33, DOI: 10.1097/00008571-199808000-00006, PMID: 9731719,</ref> while approximately 50% of Asians possess the decreased functioning CYP2D6*10 allele.<ref name="Droll_1998" />
Ligands
Following is a table of selected substrates, inducers and inhibitors of CYP2D6. Where classes of agents are listed, there may be exceptions within the class.
Inhibitors of CYP2D6 can be classified by their potency, such as:
- Strong inhibitor being one that causes at least a 5-fold increase in the plasma AUC values of sensitive substrates metabolized through CYP2D6, or more than 80% decrease in clearance thereof.<ref name=Flockhart/>
- Moderate inhibitor being one that causes at least a 2-fold increase in the plasma AUC values of sensitive substrates metabolized through CYP2D6, or 50-80% decrease in clearance thereof.<ref name=Flockhart/>
- Weak inhibitor being one that causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values of sensitive substrates metabolized through CYP2D6, or 20-50% decrease in clearance thereof.<ref name=Flockhart/>
| Substrates ↑ = bioactivation by CYP2D6 |
Inhibitors | Inducers |
|---|---|---|
Pharmacogenetics and pharmacogenomics, Pediatric Clinics of North America, Vol. 48(Issue: 3), pp. 765–81, DOI: 10.1016/S0031-3955(05)70338-2, PMID: 11411304,</ref>
Hydrocodone(link). {{{website}}}. Drugbank.
CYP2D6 and tamoxifen: DNA matters in breast cancer, Nature Reviews. Cancer, Vol. 9(Issue: 8), pp. 576–86, DOI: 10.1038/nrc2683, PMID: 19629072,</ref> (SERM)
DILTIAZEM HCL CD- diltiazem hydrochloride capsule, coated, extended release(link). DailyMed. 2017-02-01. Accessed 2019-01-31.
NIFEDIPINE EXTENDED RELEASE- nifedipine tablet, extended release(link). DailyMed. 2012-11-29. Accessed 2019-02-01.
|
Strong
Inhibition of CYP2D6 activity by bupropion, Journal of Clinical Psychopharmacology, Vol. 25(Issue: 3), pp. 226–9, DOI: 10.1097/01.jcp.0000162805.46453.e3, PMID: 15876900,</ref> (non-SSRI antidepressant)
Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine, Malaria Journal, Vol. 15, pp. 466, DOI: 10.1186/s12936-016-1509-x, PMID: 27618912, PMC: 5020452,</ref>
Medical Cannabis Adverse Effects & Drug Interactions(link). '.
Moderate
Weak
Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table(link). {{{website}}}. Indiana University School of Medicine.
Retrieved in July 2011</ref> (antiarrhythmic)
Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro, Drug Metabolism and Disposition, Vol. 31(Issue: 6), pp. 768–72, DOI: 10.1124/dmd.31.6.768, PMID: 12756210,</ref> (in opioid addiction)
Citalopram Oral Solution(link). {{{website}}}.
Escitalopram-drug-information(link). UpToDate.
Accessed 2019-05-22.
Methylphenidate and Its Under-recognized, Under- explained, and Serious Drug Interactions: A Review of the Literature with Heightened Concerns, German Journal of Psychiatry, pp. 29–42, Full text,</ref>
Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*, Clinical Pharmacology and Therapeutics, 1996, Vol. 60(Issue: 1), pp. 25–33, DOI: 10.1016/s0009-9236(96)90163-0, PMID: 8689808,</ref><ref name="Lown Bailey Fontana Janardan pp. 2545–2553">Lown, K S, Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression., The Journal of Clinical Investigation, Vol. 99(Issue: 10), pp. 2545–2553, DOI: 10.1172/jci119439, PMID: 9153299, PMC: 508096,</ref><ref name="Guengerich Brian Iwasaki Sari 1991 pp. 1838–44">Guengerich, FP, Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4., Journal of Medicinal Chemistry, 1991, Vol. 34(Issue: 6), pp. 1838–44, DOI: 10.1021/jm00110a012, PMID: 2061924,</ref>
New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine, Depression and Anxiety, Vol. 7(Issue: SUPPL. 1), pp. 24–32, DOI: 10.1002/(SICI)1520-6394(1998)7:1+3.0.CO;2-F, PMID: 9597349, Full text,</ref> Unspecified potency
In Vitro Activity of St. John's Wort Against Cytochrome P450 Isozymes and P-Glycoprotein, Pharmaceutical Biology, 2008, Vol. 42(Issue: 2), pp. 159–69, DOI: 10.1080/13880200490512034,</ref>
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes, European Journal of Clinical Pharmacology, Vol. 57(Issue: 12), pp. 847–51, DOI: 10.1007/s00228-001-0399-0, PMID: 11936702,</ref> (antipsychotic)
Inhibition of human P450 enzymes by nicotinic acid and nicotinamide, Biochemical and Biophysical Research Communications, Vol. 317(Issue: 3), pp. 950–6, DOI: 10.1016/j.bbrc.2004.03.137, PMID: 15081432,</ref> (vitamin)
|
Strong Unspecified potency
Pharmacokinetics of haloperidol: an update, Clinical Pharmacokinetics, Vol. 37(Issue: 6), pp. 435–56, DOI: 10.2165/00003088-199937060-00001, PMID: 10628896,</ref> (typical antipsychotic) |
Dopamine biosynthesis
Biosynthetic pathways for catecholamines and trace amines in the human brain<ref name="Trace amine template 1">,
The vascular effects of trace amines and amphetamines, Pharmacology & Therapeutics, Vol. 125(Issue: 3), pp. 363–375, DOI: 10.1016/j.pharmthera.2009.11.005, PMID: 19948186,</ref><ref name="Trace amine template 2">, A renaissance in trace amines inspired by a novel GPCR family, Trends in Pharmacological Sciences, Vol. 26(Issue: 5), pp. 274–281, DOI: 10.1016/j.tips.2005.03.007, PMID: 15860375,</ref><ref name="CYP2D6 tyramine-dopamine metabolism">, The endogenous substrates of brain CYP2D, European Journal of Pharmacology, Vol. 724, pp. 211–218, DOI: 10.1016/j.ejphar.2013.12.025,PMID: 24374199,</ref>  |
References
<references group="" responsive="0"></references>
Further reading
- ,
Molecular genetics of the human cytochrome P450 monooxygenase superfamily, Xenobiotica, Vol. 28(Issue: 12), pp. 1129–65, DOI: 10.1080/004982598238868, PMID: 9890157,
- ,
Cytochrome P450 CYP2D6, IARC Scientific Publications, 1999, pp. 209–29, PMID: 10493260,
- ,
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annual Review of Pharmacology and Toxicology, 2003, Vol. 43, pp. 149–73, DOI: 10.1146/annurev.pharmtox.43.100901.140251, PMID: 12171978,
- ,
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease, CNS Drug Reviews, 2006, Vol. 8(Issue: 2), pp. 159–76, DOI: 10.1111/j.1527-3458.2002.tb00221.x, PMID: 12177686, PMC: 6741688,
- ,
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates, Drug Metabolism Reviews, Vol. 36(Issue: 2), pp. 243–77, DOI: 10.1081/DMR-120034000, PMID: 15237854, Full text,
- ,
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen, Breast Cancer Research, 2010, Vol. 12(Issue: 4), pp. R64, DOI: 10.1186/bcr2629, PMID: 20731819, PMC: 2949659,
- ,
CYP2D6 gene variants and their association with breast cancer susceptibility, Cancer Epidemiology, Biomarkers & Prevention, Vol. 20(Issue: 6), pp. 1255–8, DOI: 10.1158/1055-9965.EPI-11-0321, PMID: 21527579,
External links
- Flockhart Lab Cyp2D6 Substrates Page at IUPUI
- PharmGKB: Annotated PGx Gene Information for CYP2D6
- Human CYP2D6 genome location and CYP2D6 gene details page in the UCSC Genome Browser.
| PDB gallery |
|---|
|
|
| Cytochromes, oxygenases: cytochrome P450 (Most belong to EC 1.14) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Oxidoreductases: dioxygenases, including steroid hydroxylases (EC 1.14) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Enzymes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Ad. Transform your life with W8MD's Budget GLP-1 injections from $49.99
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $49.99 for the starting dose of Semaglutide and $65.00 for Tirzepatide.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
